Anixa Biosciences, Inc.

Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • News Releases
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

September 14, 2021

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

September 7, 2021

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

August 30, 2021

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

August 25, 2021

RSS
  • « Previous
  • 1...
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • ...28
  • Next »

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

May 12, 2025

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Read More...
Apr 30, 2025

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Read More...
Apr 14, 2025

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Read More...
Copyrights © 2025 Anixa Biosciences, Inc.. All Rights Reserved.
Privacy Policy Disclaimer Sitemap